Impact of 5&agr;‐Reductase Inhibitors on Disease Reclassification among Men on Active Surveillance for Localized Prostate Cancer with Favorable Features

[1]  K. Fareed,et al.  Intermediate‐Term Outcomes for Men with Very Low/Low and Intermediate/High Risk Prostate Cancer Managed by Active Surveillance , 2017, The Journal of urology.

[2]  Liying Zhang,et al.  Active Surveillance for Intermediate Risk Prostate Cancer: Survival Outcomes in the Sunnybrook Experience. , 2016, The Journal of urology.

[3]  J. Lacy,et al.  A tale of two trials: The impact of 5α-reductase inhibition on prostate cancer (Review) , 2014, Oncology letters.

[4]  Liying Zhang,et al.  Utility of 5-alpha-reductase inhibitors in active surveillance for favourable risk prostate cancer. , 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[5]  A. Finelli,et al.  Impact of 5-alpha reductase inhibitors on men followed by active surveillance for prostate cancer: a time-dependent covariate reanalysis. , 2013, European urology.

[6]  C. Teigland,et al.  Active surveillance of very-low-risk prostate cancer in the setting of active treatment of benign prostatic hyperplasia with 5α-reductase inhibitors. , 2013, Urology.

[7]  A. Tewari,et al.  Prostate biopsy in response to a change in nadir prostate specific antigen of 0.4 ng/ml after treatment with 5α-reductase inhibitors markedly enhances the detection rate of prostate cancer. , 2012, The Journal of urology.

[8]  M. Jordá,et al.  Pathologic prostate cancer characteristics in patients eligible for active surveillance: a head-to-head comparison of contemporary protocols. , 2012, European urology.

[9]  B. Trock,et al.  Effect of treatment with 5‐α reductase inhibitors on progression in monitored men with favourable‐risk prostate cancer , 2012, BJU international.

[10]  P. Walsh.  Re: Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial. , 2012, Journal of Urology.

[11]  J. Mohler,et al.  Role of 5α-reductase inhibitors in prostate cancer prevention and treatment. , 2012, Urology.

[12]  B. Tombal,et al.  Words of wisdom: Re: Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial. , 2012, European urology.

[13]  M. Lucia,et al.  Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial , 2012, The Lancet.

[14]  Theodorus H van der Kwast,et al.  The contemporary concept of significant versus insignificant prostate cancer. , 2011, European urology.

[15]  A. Evans,et al.  Impact of 5α-reductase inhibitors on men followed by active surveillance for prostate cancer. , 2011, European urology.

[16]  Misop Han,et al.  Predicting 15-year prostate cancer specific mortality after radical prostatectomy. , 2011, The Journal of urology.

[17]  U. Capitanio,et al.  Prostate cancer in 2010: GSU: misclassification or biological progression? , 2011, Nature Reviews Urology.

[18]  R. Rittmaster,et al.  Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer. , 2008, Urology.

[19]  P. Carroll,et al.  The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance. , 2007, The Journal of urology.

[20]  I. Thompson,et al.  Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. , 2006, Journal of the National Cancer Institute.

[21]  J. Isaacs,et al.  Pharmacologic Basis for the Enhanced Efficacy of Dutasteride against Prostatic Cancers , 2006, Clinical Cancer Research.

[22]  James A Hanley,et al.  20-year outcomes following conservative management of clinically localized prostate cancer. , 2005, JAMA.

[23]  E. Klein,et al.  Outcomes of Active Surveillance after Initial Surveillance Prostate Biopsy , 2017, The Journal of urology.

[24]  P. Choyke,et al.  Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools. , 2016, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[25]  Theodorus H van der Kwast,et al.  A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial. , 2011, The Journal of urology.